All sponsors

Intra-Cellular Therapies, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS12
PHASE 3 / 2-38
RECRUITING11
READOUTS ≤12 MONTHS5
READOUT SLIPPED >6 MO44%

Delay Index: of 9 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +4.4 months). See all sponsors →

Open Intra-Cellular Therapies, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
ITI-1284 10 mg
NCT06480383
P2RecruitingGeneralized Anxiety Disorder7052027-03-16 (+3 mo)
Lumateperone
NCT05850689
P3RecruitingMajor Depressive Disorder4702027-04-05 (+18 mo)
Lumateperone high dose
NCT06706674
P3RecruitingIrritability Associated With Autism Spectrum Disorder1602027-06-21 (+4 mo)
Lumateperone high dose
NCT06690398
P3RecruitingIrritability Associated With Autism Spectrum Disorder1602027-06-21 (+4 mo)
ITI-1284 10 mg
NCT06701903
P2RecruitingGeneralized Anxiety Disorder5702027-10-14 (+4 mo)
ITI-1284
NCT06651567
P2RecruitingAgitation Associated With Alzheimer's Dementia3202027-12-28 (+3 mo)
ITI-1284
NCT06540833
P2RecruitingPsychotic Disorders; Alzheimer Disease3702028-09-30 (+13 mo)
CANDLE
NCT07747389
P3Not yet recruitingDepressive Disorder, Major5852029-09-20
ITI-1284
NCT07807865
P3RecruitingGeneralized Anxiety Disorder9002030-02-18
JNJ-99245354
NCT07856420
P3RecruitingGeneralized Anxiety Disorder7052030-09-20
Lumateperone
NCT06372964
P3RecruitingBipolar Depression3842031-10-31 (+55 mo)
Lumateperone
NCT06229210
P3RecruitingSchizophrenia; Bipolar Disorder3002032-04-28 (+53 mo)